MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Bridgebio Pharma Inc

Closed

SectorHealthcare

34.6 4.78

Overview

Share price change

24h

Current

Min

32.65

Max

34.7

Key metrics

By Trading Economics

Income

-103M

-267M

Sales

3.2M

5.9M

EPS

-1.374

Profit margin

-4,545.886

Employees

725

EBITDA

-95M

-235M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+66.78% upside

Dividends

By Dow Jones

Next Earnings

1 maj 2025

Market Stats

By TradingEconomics

Market Cap

-30M

6.7B

Previous open

29.82

Previous close

34.6

News Sentiment

By Acuity

12%

88%

14 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Bridgebio Pharma Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 wrz 2024, 17:01 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 wrz 2024, 11:00 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Peer Comparison

Price change

Bridgebio Pharma Inc Forecast

Price Target

By TipRanks

66.78% upside

12 Months Forecast

Average 55.07 USD  66.78%

High 95 USD

Low 37 USD

Based on 17 Wall Street analysts offering 12 month price targets forBridgebio Pharma Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

15

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

32.04 / 36.4Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

14 / 386 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.